Glaxosmithkline (GSK)

 

GSK Share PerformanceMore

52 week high1,745.5 11/10/16
52 week low1,363.0 24/06/16
52 week change 197.0 (13.70%)
4 week volume202,070,027 27/04/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Director/PDMR Shareholding

RNS Number: 8838F GlaxoSmithKline PLC 22 May 2017 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr P C Thomson b) Position/status President, Global Affairs c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participan...

Director/PDMR Shareholding

RNS Number: 8831F GlaxoSmithKline PLC 22 May 2017 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr R G Connor b) Position/status President, Global Manufacturing & Supply c) Initial notification/ amendment Initial Notification 2. Details of the issuer, emission allowance m...

GSK presents IIIb MUSCA study analysis in DC

GlaxoSmithKline has presented data from a post-hoc analysis of the phase IIIb MUSCA study in which first-in-class biolog...

Ph3 MUSCA study presented at ATS

RNS Number: 8589F GlaxoSmithKline PLC 22 May 2017 Issued: Monday 22 May, 2017, London UK - LSE Announcement GSK presents data at ATS on treatment effect of Nucala (mepolizumab) in severe asthma according to blood eosinophil level GlaxoSmithKline plc (LSE/NYSE:GSK) today presented data from a post-hoc analysis of the phase IIIb MUSCA study in...

Dogs of the Footsie 2017: How our 10 shares yielding 5% plus are faring

Heather Connon takes the 2017 Dogs for their first airing of the year and finds that between them they're setting a crackin...

Why this pharma giant slumped to a three-year low

This share is in freefall after delays to the approval process for one of its drugs. However, David Brenchley finds that anal...

Fund manager's favourite small-cap pharma shares

If you're looking for capital growth, don't bother with big pharma, argues fund manager Paul Mumford. He tells Lee Wild...

NEJM publication of PH3 study into Mepo in EGPA

RNS Number: 4838F GlaxoSmithKline PLC 17 May 2017 Issued: 17 th May 2017, London, UK - LSE Announcement GSK announces NEJM publication of positive phase III study investigating mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) D ouble-blind, placebo-controlled study of mepolizumab in patients with EGPA demonstra...

Fundamental DataMore

P/E ratio86.968
EPS18.8
Dividend yield4.893 %

Latest discussion posts More

  • Woody's summary on sale of GSK

    Over a holding period of more than fifteen years, I have consistently believed that GlaxoSmithKline was capable of delivering growth and realising shareholder value. Neither ...
    23-May-2017
    gamesinvestor
  • Drug Progress

    https://www.digitallook.com/news/market-live-email/gsk-makes-progress-with-mepolizumab-treatment-investec-full-year-profits-rise--2678034.html Games
    18-May-2017
    gamesinvestor
  • Re: Woody's New Fund

    ""Maybe this time next year he'll be buying back GSK for his very latest ultra-new income super fund."" Grill let's hope not, I'm not sure GSK management want anymore of his ...
    17-May-2017
    gamesinvestor

Users' HoldingsMore

Users who hold Glaxosmithkline also hold..
VODAFONE GRP.35%
BP34%
NATIONAL GRID32%
LLOYDS GRP.31%
RDS 'B'31%

Codes & Symbols

ISINGB0009252882
SymbolsGSK, LSE:GSK, GSK.L, GSK:LN, LON:GSK, XLON:GSK